X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Trevena awarded Premier to take advantage of special pricing for Olinvyk. Olinvyk contains oliceridine, an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Premier
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 04, 2023
Details:
TRV045 is a novel, selective sphingosine-1-phosphate subtype 1 receptor modulator being developed for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy treatment. Trevena is also exploring TRV045 as a potential treatment for epilepsy.
Lead Product(s): TRV045
Therapeutic Area: Neurology Product Name: TRV045
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
The funding was triggered by the first commercial sale of OLINVYK (oliceridine), contains oliceridine, an opioid, which is a Schedule II controlled substance, indicated in adults for the management of acute pain severe, in China by Jiangsu Nhwa.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CBC Group
Deal Size: $40.0 million Upfront Cash: $15.0 million
Deal Type: Financing September 06, 2023
Details:
TRV045 is a novel, selective sphingosine-1-phosphate subtype 1 receptor modulator being developed for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy treatment. Trevena is also exploring TRV045 as a potential treatment for epilepsy.
Lead Product(s): TRV045
Therapeutic Area: Neurology Product Name: TRV045
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Under the license agreement, Nhwa granted a license to develop, manufacture, and commercialize Olinvyk (oliceridine), an opioid medication that is used for the treatment of moderate to severe acute pain in adults, in China.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jiangsu Nhwa Pharmaceutical
Deal Size: $5.5 million Upfront Cash: $2.5 million
Deal Type: Licensing Agreement May 31, 2023
Details:
Olinvyk (oliceridine), recently approved in China, is an opioid, schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
TRV045 is a novel, selective sphingosine-1-phosphate subtype 1 receptor modulator being developed for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy treatment. Trevena is also exploring TRV045 as a potential treatment for epilepsy.
Lead Product(s): TRV045
Therapeutic Area: Neurology Product Name: TRV045
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
Olinvyk (oliceridine), an opioid, which is a Schedule II controlled substance with a high potential for abuse similar to other opioids. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
TRV045 is a novel, selective sphingosine-1-phosphate subtype 1 receptor modulator being developed for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy treatment. Trevena is also exploring TRV045 as a potential treatment for epilepsy.
Lead Product(s): TRV045
Therapeutic Area: Neurology Product Name: TRV045
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
OLINVYK (oliceridine) study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects.
Lead Product(s): Oliceridine
Therapeutic Area: Neurology Product Name: Olinvyk
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
